CareDx publishes KOAR analysis tying early AlloSure Kidney patterns to graft outcomes

CareDx announced the third KOAR manuscript was published in Transplantation. The analysis covered 1,137 kidney transplant recipients across 56 centers and grouped them by AlloSure Kidney donor-derived cell-free DNA trajectories during the first four months after transplant. Persistent elevation was tied to a nine-fold higher incidence of allograft loss than consistently low levels. Late elevation was independently associated with donor-specific antibody development, rejection and graft loss, with 8.8% graft loss in that group. Transient elevations that resolved were not associated with worse outcomes, with graft loss of 2.9% versus 2.2% for consistently low. Most recipients, 83.7%, had consistently low levels and favorable three-year outcomes. Baseline graft function and delayed graft function rates were similar across groups. No financial terms or guidance were disclosed.